Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma
- Pontus K E Börjesson
- , Ernst J. Postema
- , Jan C. Roos
- , David R. Colnot
- , Henri A M Marres
- , Mathijs H. Van Schie
- , Gerd Stehle
- , Remco De Bree
- , Gordon B. Snow
- , Wim J G Oyen
- , Guus A M S Van Dongen*
*Corresponding author for this work
- Department of Obstetrics and Gynaecology
- Boehringer Ingelheim GmbH
Research output: Contribution to journal › Article › Academic › peer-review